Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SEG-2022-01 Patient Characteristics and Treatment Patterns From Early Crizanlizumab Use in Real-world Setting: Preliminary Analysis From Select Sickle Cell Centers

NCT06662825 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT06662825
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06662825 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SEG-2022-01 Patient Characteristics and Treatment Patterns From Early Crizanlizumab Use in Real-world Setting: Preliminary Analysis From Select Sickle Cell Centers
Lead sponsor
Novartis
Phase
Observational
Overall status
Completed
Start date
December 13, 2022
Completion date
November 1, 2023
Enrollment
376 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease